Revolution Medicines

Revolution Medicines

Yahoo Finance • 2 days ago

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.

Key Points Revolution Medicines' cancer drugs in development could establish new standards of care in some niches. The biotech company may launch its leading candidate within the next year. Despite a strong outlook, the stock still looks... Full story

Yahoo Finance • 3 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Erasca, Inc. of Class Action Lawsuit and Upcoming Deadlines – ERAS

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS).   Such investors are advised to contact Danielle Peyton at ne... Full story

Yahoo Finance • 10 days ago

After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

Quick Read Legend Biotech (LEGN) generates $1 billion in CAR-T revenue with J&J already embedded as acquirer, yet trades at roughly half its $58 analyst price target. Aleniglipron posted 16% placebo-adjusted weight loss at 44 weeks, placi... Full story

Yahoo Finance • 17 days ago

SCHA vs. ISCB: Which Small-Cap ETF Is the Better Buy for Investors in 2026?

Investors seeking small-cap exposure often prioritize low fees and broad diversification. Both the Schwab U.S. Small-Cap ETF (NYSEMKT:SCHA) and the iShares Morningstar Small-Cap ETF (NYSEMKT:ISCB) track hundreds of smaller U.S. companies,... Full story

Yahoo Finance • 20 days ago

Pancreatic Cancer Drug Milestone Affirms Why Revolution Medicines Inc. (RVMD) is a Hot Stock to Buy

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best hot stocks to buy for June. On June 8, RBC Capital reiterated an Outperform rating on Revolution Medicines Inc. (NASDAQ:RVMD) and a $182 price target.Pancreatic Cancer Drug Milesto... Full story

Yahoo Finance • 22 days ago

Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?

Is VRTX a good stock to buy? We came across a bullish thesis on Vertex Pharmaceuticals Incorporated on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on VRTX. Vertex Pharmaceuticals Incorpora... Full story

Yahoo Finance • 23 days ago

Can Revolution Medicines Be a Game-Changer Stock?

Key Points Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs. It is a likely target for a buyout by lar... Full story

Yahoo Finance • 25 days ago

Top Midday Gainers

Tango Therapeutics' (TNGX) initial results from a phase 1/2 trial of vopimetostat in combination wit PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 25 days ago

Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?

We just covered the 10 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller. Revolution Medicines (NASDAQ:RVMD) ranks #7 (see 5 Best Non-AI Stocks to Buy According to Billionaire Stanley Druckenmiller). Druckenmiller’... Full story

Yahoo Finance • 29 days ago

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech

Key Points Invesco Pharmaceuticals ETF has a significantly lower five-year maximum drawdown and lower volatility profile than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF offers a more diversified approach with 151... Full story

Yahoo Finance • last month

Revolution Medicines' Daraxonrasib Redefines Survival In Pancreatic Cancer; Stock Up

(RTTNews) - Revolution Medicines, Inc. (RVMD) unveiled pivotal Phase 3 results from its RASolute 302 trial of Daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma, showing unprecedented survival gains compared to... Full story

Yahoo Finance • last month

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced detailed resul... Full story

Yahoo Finance • last month

Is Daraxonrasib’s Phase 3 Pancreatic Cancer Data And EQRx Deal Altering The Investment Case For Revolution Medicines (RVMD)?

Earlier in May 2026, Revolution Medicines reported that its RAS(ON) inhibitor daraxonrasib delivered what it called unprecedented overall survival benefit in the pivotal Phase 3 RASolute 302 trial for metastatic pancreatic cancer, while al... Full story

Yahoo Finance • 2 months ago

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals(NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 2 months ago

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

Boxer Capital Management increased its stake in Kodiak Sciences(NASDAQ:KOD) during the first quarter, adding 225,000 shares in a transaction estimated at $5.81 million based on quarterly average pricing, according to a May 15, 2026, SEC fi... Full story

Yahoo Finance • 2 months ago

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares

On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 2 months ago

Small-Cap ETF Showdown: Schwab's SCHA vs. iShares' IJR

The Schwab U.S. Small-Cap ETF(NYSEMKT:SCHA) offers lower costs and broader market coverage, while the iShares Core S&P Small-Cap ETF(NYSEMKT:IJR) provides a more concentrated portfolio with higher liquidity. Both funds serve as low-cost g... Full story

Yahoo Finance • 2 months ago

Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best performing healthcare stocks so far in 2026. Revolution Medicines, Inc. (NASDAQ:RVMD) announced on May 1 that the U.S. Food and Drug Administration (FDA) issued a “safe to proceed... Full story

Yahoo Finance • 2 months ago

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentationRASolute 302 data planned fo... Full story

Yahoo Finance • 2 months ago

Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?

Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries... Full story